...
首页> 外文期刊>ACP Journal Club >Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes
【24h】

Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes

机译:罗格列酮在心血管事件方面不亚于二甲双胍加磺脲类药物,但增加了2型糖尿病的HF和骨折风险

获取原文
获取原文并翻译 | 示例
           

摘要

In patients with type 2 diabetes, rosiglitazone added to metforminn(MFN) or sulfonylurea (SFU) was noninferior to MFNnplus SFU for overall cardiovascular safety but increased risk fornheart failure and fractures.
机译:对于2型糖尿病患者,在总体心血管安全方面,加入二甲双胍(MFN)或磺酰脲(SFU)的罗格列酮不逊于MFNnplus SFU,但增加了心力衰竭和骨折的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号